Oncolytics Biotech Reports Pelareorep Combo Doubles Response Rate in Advanced Anal Cancer Trial
Reuters
Oct 28
Oncolytics Biotech Reports Pelareorep Combo Doubles Response Rate in Advanced Anal Cancer Trial
Oncolytics Biotech Inc. has announced updated results from the squamous cell anal carcinoma (SCAC) cohort of the GOBLET study, evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later (≥2L) metastatic SCAC. The combination achieved an objective response rate $(ORR)$ of 30% among 20 evaluable patients, which is more than double the 13.8% historical benchmark for the only FDA-approved immunotherapy in this setting. The median duration of response was 15.5 months, compared to 9.5 months for the current standard of care. These results have already been presented, and additional efficacy data are expected to be reported as patient follow-up continues. Oncolytics plans to discuss a potential single-arm accelerated approval study with the U.S. Food and Drug Administration (FDA) in the first quarter of 2026, with a potential study launch date in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN08497) on October 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.